Doctors, Big Pharma Profit On Blindness, Taxpayers Lose
The Article: An effective eye drug is available for $50. But many doctors choose a $2,000 alternative. by Peter Whoriskey and Dan Keating in The Washington Post.
The Text: The two drugs have been declared equivalently miraculous. Tested side by side in six major trials, both prevent blindness in a common old-age affliction. Biologically, they are cousins. Theyāre even made by the same company.
But one holds a clear price advantage.Avastin costs about $50 per injection.
Lucentis costs about $2,000 per injection.
Doctors choose the more expensive drug more than half a million times every year, a choice that costs the Medicare program, the largest single customer, an extra $1 billion or more annually.
Spending that much may make little sense for a country burdened by ever-
rising health bills, but as is often the case in American health care, there is a certain economic logic: Doctors and drugmakers profit when more-costly treatments are adopted.